13F Pro Quality Score

20.3/100

Rank #2,775 of 2,961 stocks

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.

Email me the moment this company reports earnings
AI Research Report
Two-page plain-English analysis: business, thesis, and three scenarios for the next two years. Refreshed every quarter.
Upgrade to Pro
Pro: 5 reports/month · Pro+: unlimitedOpinion, not investment advice. Do your own research.

Unusual Activity in ACON

Events flagged as statistical outliers against ACON's own multi-year baseline — not fixed dollar thresholds.

  • Insider cluster2026-08-17

    6 insiders bought $125,670 of ACON in 30 days — 7.0σ above this company's 2-year norm

    View source filing →
  • Insider cluster2026-08-14

    5 insiders bought $109,681 of ACON in 30 days — 5.7σ above this company's 2-year norm

    View source filing →

ACON Stock Analysis & AI Quality Score

Data updated 2026-09-11

AI stock analysis and institutional research for Aclarion, Inc. (ACON), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores ACON at 20.3/100 on a 32-signal composite quality model, placing it at rank #2,775 of 2,961 stocks — the bottom half of the AI-ranked universe. Based on the latest XBRL financial filings (Q2 2026), Aclarion, Inc. reports quarterly revenue of $25.2K, net income of $-2.7M. Top institutional holders of ACON by reported 13-F value include BRIDGEWAY CAPITAL MANAGEMENT, CAPTRUST FINANCIAL ADVISORS, VANGUARD FIDUCIARY, based on the most recent SEC filings. ACON trades on the Nasdaq exchange and files with the SEC under CIK 1635077. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate ACON daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Aclarion, Inc. directly from SEC EDGAR. Aclarion, Inc.'s 13F Pro composite quality score has ranged between 17 and 23 since 2026, currently 20.3 — an improving long-term trajectory across 8 quarterly and live scoring snapshots.

Fun facts about Aclarion, Inc.

Quirks, history, and lore behind ACON — the kind of stuff that makes a stock memorable.

  • 1
    The Basics
    A small-cap healthcare technology company · listed on Nasdaq · headquartered in Colorado · focused on making sense of one of medicine's most stubborn problems.
  • 2
    The Numbers
    With a micro-cap valuation and a very small headcount, this is a development-stage company where the science, not the revenue, is the whole pitch right now.
  • 3
    The History
    The company grew out of research into spinal disc degeneration, working for years to commercialize a diagnostic tool that most physicians didn't even know they were missing.
  • 4
    The Secret
    Its core technology uses MRI-based biomarkers — specifically chemical signals — to help pinpoint which spinal disc is actually causing a patient's chronic back pain.
  • 5
    The Lore
    Chronic low back pain is one of the costliest conditions in medicine, yet pinpointing the exact disc responsible has historically been more art than science — this company is trying to change that.
  • 6
    The Giveaway
    Its flagship platform, Nociscan, analyzes NMR spectroscopy data from MRI scans to chemically identify painful discs — a needle-in-a-haystack solution for discogenic back pain.
▶ Think you know your stocks? Play the Daily Ticker

Revenue

Q2 2026

$25.2K

Net Income

Q2 2026

$-2.7M

ROIC

Q2 2026

-68.2%

Period

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro

Revenue

+65.6% YoY
$75.7KFY 2025
FY22 $60.4KFY23 $75.4KFY24 $45.7KFY25 $75.7K

Net Income

-3.4% YoY
$-7.2MFY 2025
FY22 $-7.1MFY23 $-4.9MFY24 $-7.0MFY25 $-7.2M

Operating Income

-27.9% YoY
$-7.1MFY 2025
FY22 $-5.6MFY23 $-4.9MFY24 $-5.5MFY25 $-7.1M

EPS (Diluted)

+99.8% YoY
$-4.54FY 2025
FY22 $-0.41FY23 $-26594.00FY24 $-2492.97FY25 $-4.54

Total Assets

+543.9% YoY
$13.7MFY 2025
FY22 $2.9MFY23 $2.5MFY24 $2.1MFY25 $13.7M

Op. Cash Flow

-35.9% YoY
$-7.2MFY 2025
FY22 $-4.9MFY23 $-3.6MFY24 $-5.3MFY25 $-7.2M

Free Cash Flow

-36.2% YoY
$-7.2MFY 2025
FY22 FY23 $-3.6MFY24 $-5.3MFY25 $-7.2M

Get alerted when ACON's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Aclarion, Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)
XBRL financial facts (revenue, EPS, margins)
Insider transactions (Form 4)
Institutional 13F holdings
Quality rankings (32 signals)
AI analyst debates & daily meetings
Historical financial trends
Peer comparison & sector analysis

Put ACON on your watchlist

Track score changes the day Aclarion, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Is ACON a good stock to buy?

13F Pro's AI-powered analysis of Aclarion, Inc. (ACON) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for ACON are available on the ACON stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. ACON is classified as a small company.

Which hedge funds own ACON?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling ACON. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Aclarion, Inc.'s investment landscape.